Migdal Insurance & Financial Holdings
ABCL icon

Migdal Insurance & Financial Holdings’s AbCellera Biologics ABCL Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-595
Closed -$9K – 600
2021
Q4 		$9K Buy
+595
New +$9.03K ﹤0.01% 605

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
DB
DCVC Bio Palo Alto, California $313K AUM
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Harvard Management Company
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return

Migdal Insurance & Financial Holdings's ABCL Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of AbCellera Biologics (ABCL) in Q1 2022, closing a stake of 595 shares — an estimated $9K sold.

Migdal Insurance & Financial Holdings first reported a position in ABCL in Q4 2021 and held it in 1 quarter. The position peaked at $9K in Q4 2021. 130 funds tracked by Wall St. Rank hold ABCL as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining AbCellera Biologics position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 595 AbCellera Biologics shares in Q1 2022, an estimated $9K.
  • Migdal Insurance & Financial Holdings first reported a position in AbCellera Biologics in Q4 2021 and held it in 1 quarter.
  • Migdal Insurance & Financial Holdings's AbCellera Biologics position peaked at $9K in Q4 2021.
  • 130 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.